0
Elicera Therapeutics is an innovative biotechnology company with a focus on immunotherapy against cancer. The company develops pioneering treatments based on CAR-T cell therapy and oncolytic viruses against cancer with strong support from international collaborations and significant soft financing.
The company has a solid pipeline of promising treatments. One of these is CAR-T cell therapy, where the patient's own immune cells are modified to attack cancer cells. This therapy has shown promising results, particularly against blood cancers, and Elicera Therapeutics is at the forefront of its fourth-generation CAR-T cell therapy. Another part is oncolytic viruses. These genetically modified viruses infect and destroy cancer cells, while activating the body's immune system to further fight the cancer.
Elicera Therapeutics is currently conducting two clinical trials with its oncolytic virus and CAR-T cell therapy, ELC-100 (phase I-IIa), ELC-301 (phase I-II). Elicera's unique platform, iTANK, strengthens the effectiveness of CAR-T cells and opens up lucrative partnerships and licensing agreements. With a strong financial position, Elicera Therapeutics is well positioned to take the next step in its development. ELC-100 cost is sponsored which shows the potential of it.
The company is being traded on Stockholm First north with ticker Elic, with a mcap of ~80 mSek with ~30 mSek in cash, insiders own 30% of company so limited free float, so the potential is really big here if you compare with valuation of other biotech's working in Car-T sector. Cash is excepted to take company into mid 2026, but as their are warrants Elicera TO1 out that is to be subscribed Q1 2025, the cash position will likely increase further thus no need of capital injection for long time. ELC-100 received ODD from FDA 2025-01-13 so this further strengthens the potential.
Shortterm triggers: Completion of ELC-100 phase 1 H1-2025 and interim of three patients H1 2025 on ELC-301. Both of these will be high drivers for the valuation if positive.
CEO has stated that they aim to outlicense their iTANK platform, and CEO hopes it will be attracting interest near term.
This stock can be a real winner 2025 given positive news, with the low valuation, a 500% share price (mcap 400 mSEK) increase should not be impossible.
The company has a solid pipeline of promising treatments. One of these is CAR-T cell therapy, where the patient's own immune cells are modified to attack cancer cells. This therapy has shown promising results, particularly against blood cancers, and Elicera Therapeutics is at the forefront of its fourth-generation CAR-T cell therapy. Another part is oncolytic viruses. These genetically modified viruses infect and destroy cancer cells, while activating the body's immune system to further fight the cancer.
Elicera Therapeutics is currently conducting two clinical trials with its oncolytic virus and CAR-T cell therapy, ELC-100 (phase I-IIa), ELC-301 (phase I-II). Elicera's unique platform, iTANK, strengthens the effectiveness of CAR-T cells and opens up lucrative partnerships and licensing agreements. With a strong financial position, Elicera Therapeutics is well positioned to take the next step in its development. ELC-100 cost is sponsored which shows the potential of it.
The company is being traded on Stockholm First north with ticker Elic, with a mcap of ~80 mSek with ~30 mSek in cash, insiders own 30% of company so limited free float, so the potential is really big here if you compare with valuation of other biotech's working in Car-T sector. Cash is excepted to take company into mid 2026, but as their are warrants Elicera TO1 out that is to be subscribed Q1 2025, the cash position will likely increase further thus no need of capital injection for long time. ELC-100 received ODD from FDA 2025-01-13 so this further strengthens the potential.
Shortterm triggers: Completion of ELC-100 phase 1 H1-2025 and interim of three patients H1 2025 on ELC-301. Both of these will be high drivers for the valuation if positive.
CEO has stated that they aim to outlicense their iTANK platform, and CEO hopes it will be attracting interest near term.
This stock can be a real winner 2025 given positive news, with the low valuation, a 500% share price (mcap 400 mSEK) increase should not be impossible.
15/1 2025 20:02 c3po 0124194 "This stock can be a real winner 2025 given positive news, with the low valuation, a 500% share price (mcap 400 mSEK) increase should not be impossible."
500% er lidt under mit CAGR de seneste 5 aar, saa jeg takker nej
500% er lidt under mit CAGR de seneste 5 aar, saa jeg takker nej
21/1 2025 14:58 Jonau85 0124326 Gothenburg, January 21, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the first patient in the CAR T-cell study CARMA, which evaluates the efficacy of ELC-301 against B-cell lymphoma, has been successfully treated. The one-month follow-up after treatment shows that the patient achieved a complete response with only very mild side effects. The treatment outcome will now be presented at the Cancer Crosslinks conference in Oslo on January 23.
News from the first patient from ELC-301, patient at lowest dosage has complete response on the medication, meaning the cancer has been removed, huge news!!
News from the first patient from ELC-301, patient at lowest dosage has complete response on the medication, meaning the cancer has been removed, huge news!!
